Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia

Background Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by leukocytosis and an accumulation of granulocytes and their precursors. Cortactin is an actin-binding protein substrate of Src kinase. High cortactin expression in many hematological malignancies has been correlated with adverse prognostic factors. Aim The aim of our study was to measure cortactin levels in patients with CML at diagnosis and correlate such levels with other prognostic factors. Patients and methods This is a case–control study that was executed at hematology unit, Ain-Shams University Hospital during the period between January 2021 and October 2021. The study included 25 newly diagnosed patients with chronic phase CML and 25 healthy controls. Accelerated phase and blast crisis were excluded from the study. Results Cortactin level at diagnosis was higher in the patients group compared with the control group (71.04 ± 20.04 vs. 36.8 ± 11.6%, P<0.001). Cortactin level was significantly higher in patients who did not achieve complete hematological remission (CHR) at 3 months in comparison with those who achieved CHR (88.49 ± 8.02 vs. 61.23 ± 17.98, P<0.001). Patients who failed to attain CHR at 3 months had a significantly worse prognostic score at diagnosis using Sokal, Hasford, and ELTS scores (P=0.016, 0.035, and 0.009, respectively), but this did not apply to EUTOS score (P=0.089). Conclusion Higher cortactin levels are associated with delayed CHR in newly diagnosed patients with chronic phase CML, and it can be used as a prognostic marker for patients with CML at diagnosis.

show abstract

Cortactin

Elrazzaz

Ahmed

Eissa

et al. 2022

The Egyptian Journal of Haematology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia

Abstract: Pui 2013). Bone marrow (BM) relapse most common than extramedullary infiltration such as central nervous system (CNS); with a generally worse survival (Malempati et al., 2007). Several studies have demonstrated the role

Cited by 1 publication

References 13 publications

Cortactin

Cortactin

Contact Info

Product

Resources

About